



THE UNITED REPUBLIC OF TANZANIA
MINISTRY OF HEALTH



TANZANIA MEDICINES AND MEDICAL DEVICES AUTHORITY

**PROTOCOL FOR LABORATORY PERFORMANCE EVALUATION OF HEPATITIS B
SURFACE ANTIGEN**

FIRST EDITION

OCTOBER, 2025

TABLE OF CONTENTS

TABLE OF CONTENTS	i
ACKNOWLEDGEMENTS	iii
FOREWORD	iv
ABBREVIATIONS	v
DEFINITION OF TERMS	vi
1 Introduction	1
2 Study objectives.	2
2.1 Overall objective	2
2.2 Specific objectives	2
3 Study implementation.	2
3.1 Performance evaluation laboratory	2
3.2 Training, performance evaluation and supervision	2
3.3 Safety	3
3.4 Storage of assays	3
4 Specimens	4
4.1 Clinical performance specimen panel	4
4.2 Specimen collection and storage	4
4.3 Characterization of the Hepatitis B specimen reference panel	4
5 Laboratory testing	5
5.1 Review of the instructions for use	5
5.2 Clinical performance panel	5
5.3 Criteria to continue testing.	6
5.4 Lot-to-lot variation panel	6
5.5 Interpretation of results	6
5.6 Recording test results	6
6 Quality control and interpretation of test results	7
6.1 Test kit controls	7
6.2 Internal control lines for rapid diagnostic tests	7
6.3 External quality control specimen	7
6.4 Competency panels	7
6.5 Limits of acceptability	8

7	Analysis of data	8
7.1	Invalid devices	8
7.2	Inter-reader variability	8
8	Clinical performance characteristics	8
8.1	Sensitivity	9
8.2	Specificity	9
8.3	Confidence intervals	9
8.4	Initial and final sensitivity and specificity	9
9	Analytical performance characteristics	9
9.1	Results from lot-to-lot variation panel	9
10	Laboratory professional's appraisal	9
11	Report preparation and dissemination.	10
12	Acceptance criteria	10
13	Materials and supplies	10
14	Roles and responsibilities	10
14.1	Responsibilities of the Evaluating Laboratory	10
14.2	Responsibilities of TMDA	10
15	Bibliography	11
16	Annex 1	11
16.1	Operational characteristics and ease of use	11

ACKNOWLEDGEMENTS

This first edition of the protocol intends to establish a well-documented procedure for conducting performance evaluation of in vitro diagnostic tests for Hepatitis B Virus antigen (HBsAg). This protocol serves as a guide and set a clear expectation on performance evaluation reports that are mandatory in marketing authorization applications and reduce round of request for additional data which used to prolong the evaluation time and hence delays in approval. It is my hope that the information included in this protocol will assist manufactures and/or applicants to conduct performance evaluation studies in Tanzania Mainland and subsequently expedite the verification process of the results by the Authority.

My sincere gratitude is extended to the TMDA staff and other experts who gave their valuable time and experience in the development of this protocol. The acknowledgements are particularly extended to Ms. Rehema Mariki, Dr. Goodluck Gatora, Mr. Christian Kapinga, Ms. Edina Zebedayo, Mr. Edinanth Gareba, Mr. Octavian Aron Ngoda, Mr. James Tanguye, Ms. Emmanuela Mkalawa and Ms. Adelina G. Gadiye from Muhimbili National Hospital (MNH). Moreover, it is with honor I appreciate the outstanding technical contribution offered by Prof. Willy Urassa, a World Health Organization (WHO) consultant, from the early stages of development of this protocol.

I would like to sincerely thank and appreciate the contribution of the International Medical Devices Regulators Forum (IMDRF), the World Health Organization (WHO) as well as Medical Device Coordination Group (MDCG) established by European Union (EU) for making their guidelines accessible for referencing.

The proper use and implementation of this protocol will ensure that the Hepatitis B Virus antigen (HBsAg) Assays which have been designated to be of public health importance will perform clinically as claimed by manufacturers.



Dr. Kissa Mwamwitwa
Director, Medical Devices and Diagnostics Control

FOREWORD

Hepatitis B continues to pose a significant public health challenge in Tanzania, with far-reaching consequences for both individual health and national healthcare systems. As a viral infection that can lead to chronic liver disease, cirrhosis, and liver cancer, timely and accurate diagnosis is crucial in the management and prevention of Hepatitis B. Early detection not only enables effective treatment but also helps in reducing transmission within communities.

In response to the growing need for reliable diagnostics, the Tanzania Medicines and Medical Devices Authority (TMDA) has developed this comprehensive protocol for the performance evaluation of Hepatitis B diagnostic tests. This protocol is designed to ensure that diagnostic tests meet the highest standards of accuracy, reliability, and quality, providing healthcare professionals with the confidence to diagnose and manage Hepatitis B effectively. The evaluations will be conducted in laboratories certified to international standards including ISO 17025 (General Requirements for the Competence of Testing and Calibration Laboratories) and ISO 15189 (Medical Laboratories — Requirements for Quality and Competence).

This protocol and the certified laboratories are key components of Tanzania's broader efforts to combat Hepatitis B, strengthen its healthcare infrastructure, and ensure the availability of accurate, reliable diagnostic services for the benefit of all Tanzanians. Through these initiatives, we aim to improve health outcomes, reduce the burden of Hepatitis B, and support our country's progress toward eliminating viral hepatitis as a public health threat.

Applicants and manufacturer are henceforth compelled to read the details as provided for in this protocol to streamline and expedite the approval process of diagnostics targeting Tanzania market. Together with the existing legal framework including TMDA Act and Regulations in force, applicants will also be required to refer the ISO 20916 standard when conducting performance evaluation studies. Studies done comprehensively and pursuant to this protocol will allow for generation of adequate data and subsequent authorization of in-vitro diagnostics for marketing in Tanzania.

It is envisaged that the protocol will be helpful to our stakeholders and harmonize the performance evaluation process and therefore any suggestions for improvement of the same are likewise welcomed.



Dr. Adam M. Fimbo
Director General

ABBREVIATIONS

EIA	-	Enzyme Immunoassay
HBsAg	-	Hepatitis B Surface Antigen
IFU	-	Instructions for use
IVD	-	Invitro Diagnostic
PI	-	Principal Investigator
QC	-	Quality Control
TMDA	-	Tanzania Medicines and Medical Devices Authority

DEFINITION OF TERMS

Authority

Means the Tanzania Medicines and Medical Devices Authority or the acronym “TMDA” established under section 4(1) of the Act.

Applicant

Means any person or institution or company that applies formally for performance evaluation of IVD in Tanzania.

Clinical Performance

Means ability of an IVD to yield results that are correlated with a particular clinical condition/ physiological state in accordance to target population and intended use.

Conformity Assessment

Means the systematic examination of evidence generated and procedures undertaken by the manufacturer, under requirements established by the Authority, to determine that an IVD is safe and performs as intended by the manufacturer and, therefore, conforms to the Essential Principles of Safety and Performance of Medical Devices.

Diagnostic Sensitivity

Means the ability of a device to identify the presence of a target marker associated with a particular disease or condition.

Diagnostic Specificity

Means the ability of a device to recognize the absence of a target marker associated with a particular disease or condition.

Ethics Committee (EC)

Means an independent body composed of members with expertise in both scientific and non-scientific arenas which functions to ensure the protection of human rights and the well-being of research subjects based on six basic principles of autonomy, justice, beneficence, no maleficence, confidentiality and honesty.

Error rate

Means a measure of the degree of prediction error of a model made with respect to the true model.

In Vitro Diagnostics Devices

Means a device whether used alone or in combination, intended by the manufacturer for the in vitro examination of specimens derived from the human body and animals principally to provide information for diagnostic, monitoring or compatibility purposes. IVD include reagents, calibrators, control materials, specimen receptacles, software, and related instruments or apparatus or other articles and are used for example for the following test purposes: diagnosis, aid to diagnosis, screening, monitoring, predisposition, prognosis, prediction and determination of physiological status.

Manufacturer

Means any person or a firm that is engaged in the manufacture of IVDs.

Negative likelihood ratio (LR-)

Means a probability that a person with the disease tested negative divided by the probability that a person without the disease tested negative.

Negative predictive value

Means the ratio of subjects truly diagnosed as negative to all those who had negative test results (including patients who were incorrectly diagnosed as healthy).

Performance evaluation

Means the assessment and analysis of data to establish or verify the performance (analytical performance and where applicable, clinical performance) of an IVD.

Positive predictive value

Means the ratio of patients truly diagnosed as positive to all those who had positive test results (including healthy subjects who were incorrectly diagnosed as patient).

Positive likelihood ratio (LR+)

Means probability that a positive test would be expected in a patient divided by the probability that a positive test would be expected in a patient without a disease.

1 Introduction

This protocol outlines the necessary procedures for conducting the performance evaluation of HBsAg rapid tests submitted to the Tanzania Medicines and Medical Devices Authority (TMDA) for market authorization. It is important to note that this protocol is not intended to replace the validation and verification studies that manufacturers must conduct to meet the full requirements of the TMDA product dossier.

The primary purpose of the performance evaluation is to assess the accuracy of HBsAg assays, comparing their results against established performance benchmarks. These benchmarks include key diagnostic characteristics such as sensitivity, specificity, positive and negative predictive values, and overall accuracy. Additionally, the evaluation examines several operational aspects of the assays, including their suitability for use in laboratory environments or other testing settings with limited infrastructure. This protocol specifically covers assays used for the detection of HBsAg.

To ensure comprehensive and representative evaluation, the HBsAg specimen reference panel will consist of a minimum of 400 HBsAg-positive and 1000 HBsAg-negative venous or capillary whole blood, serum, or plasma specimens sourced from Tanzania.

These protocols should be read together with the current TMDA Guidelines for Conducting Performance Evaluation of In-vitro Diagnostic Devices submitted for marketing authorization which among other things provides for format of clinical performance study report based on the class of the IVD medical device.

2 Study objectives.

2.1 Overall objective

The overall objective is to evaluate and compare the accuracy of currently available HBsAg rapid diagnostic tests for detection of HBsAg against established performance criteria.

2.2 Specific objectives

The specific objectives of the performance evaluation are:

- To determine the sensitivity and specificity of currently available HBsAg rapid diagnostic tests for the detection of antigen to Hepatitis B as compared to a reference algorithm (Enzyme Immunoassay (EIA) followed by Nucleic Acid Test (NAT)) and compare them to predefined acceptance criteria for market authorization by TMDA.
- To assess lot-to-lot variation
- To assess inter-reader variability (for subjectively read assays)
- To describe and assess the operational characteristics and ease of use of HBsAg tests.

3 Study implementation.

3.1 Performance evaluation laboratory

The performance evaluation laboratories shall hold one of the following certifications for quality management within the laboratory: ISO 17025 *General requirements for the competence of testing and calibration laboratories*, ISO 15189 (*Medical laboratories - Requirements for quality and competence*) or equivalent.

The Head of the Laboratory will act as the Principal Investigator (PI) for the work performed by the laboratory.

3.2 Training, performance evaluation and supervision

The following issues are key to minimizing error and maximizing the value of this performance evaluation:

- The PI will be responsible for training the laboratory professionals on the details of the evaluation protocol and on the performance of each assay undergoing evaluation.
- Only those personnel who have received specific training for a particular assay evaluation will be employed.
- Accurate record keeping is crucial to the success of the evaluation and the PI will be responsible for ensuring that all data required for the evaluation are recorded on the agreed data collection sheets and are accurate and up to date.
- It is important to plan work in advance and follow standard operating procedures as prepared and controlled by the laboratory.
- To reduce the risk of adding an incorrect specimen to a test device/well, before starting the test run, the operator will prepare worksheets and label all tubes, dilution vessels, test devices or plates with the specimen's unique number.

- Because objective, machine-generated, permanent results for simple/rapid diagnostic tests are not feasible, it is essential that the PI emphasizes to the operator performing the tests the need for accurate recording of results and recordkeeping.
- To minimize the risk of error, it is recommended that the results are read and recorded independently by three trained staff members.
- To allow immediate correction of erroneous recording of results (rather than differences in visual interpretation), the PI or designee should assess the results as soon as possible to allow her/him to return to the original test device to investigate apparently discordant readings.
- For the performance evaluations performed at the laboratory, at least one representative result from both Hepatitis B antigen positive and negative specimens will also be recorded by taking electronic images. Unexpected test results will also be digitally recorded as well as an image of the instructions for use.

3.3 Safety

HIV, hepatitis B and hepatitis C and other viruses are transmissible by blood and body fluids. Therefore, all types of specimens (including venous and capillary whole blood, serum/plasma, oral fluid, etc.) must be handled as potentially infectious. Appropriate precautions to minimize infectious hazards must be taken at all stages from the collection of specimens to the disposal of used materials from the laboratory. The WHO Guidelines on HIV Safety Precautions, and Guidelines for the Safe Transport of Specimens (WHO/EMC/97.3) and the evaluating site's guidelines on laboratory safety should be followed carefully by the laboratory staff.

3.4 Storage of assays

All reagents must be stored as indicated in the instructions for use. Some assays or components may not need refrigeration. If refrigerated storage space is inadequate to store the entire test kit, they may be divided so that labile reagents can be refrigerated separately from the non-labile supplies. Calibrated thermometers are placed at each location where reagents and specimens are stored, i.e. ambient, refrigerator and freezer. Temperatures are recorded daily on the laboratory temperature logs. The lot numbers of the test kits received/used, and their expiry dates are recorded on the individual run worksheets.

Two separate production lots (with different lot numbers and different expiry dates) will be requested for evaluation, according to the following definition of a lot: "The amount of material that is uniform in its properties and has been produced in one process or series of processes. The material can be either starting material, intermediate material or finished product." Each lot shall comprise different production (or manufacturing, purification, etc.) runs of critical reagents. Furthermore, lots must be sourced from a representative production run and not produced especially for the purpose of this evaluation. TMDA will verify this information before the product assessment has been finalized.

4 Specimens

4.1 Clinical performance specimen panel

A panel of 1400 well-characterized venous or capillary whole blood serum/plasma clinical specimen, including 400 HBsAg positive specimens and 1000 HBsAg negative specimens, will be used for this evaluation.

4.2 Specimen collection and storage

As much as possible, specimens used in this evaluation will be representative of the intended use population, i.e. from clients screened for Hepatitis infection in different regions in Tanzania.

The panel may consist of the following specimens:

- Left-over specimens from clients attending Hepatitis infection testing services.
- Left-over specimens from known Hepatitis B antigen positive patients from Hepatitis clinic.
- Rejected blood units from blood donation centers, rejected because they were found to be infected with blood borne pathogens including HIV, Hepatitis B, Hepatitis C, Syphilis etc.

After removing all the specimen identifiers, specimens are assigned a unique identification number at the laboratory. Once the specimens have been processed and labelled, they are aliquoted and frozen immediately at -70°C. During the period of testing, the specimens are stored at 2 - 8 °C and this time period does not exceed one week. After the completion of testing, they are again stored at -70 °C.

The number of freeze-thaw cycles should be recorded. Each aliquot should not undergo more than five freeze/thaw cycles, as this has been shown not to affect the stability of antibodies. For assays also detecting antigens (4th generation assays), aliquots with a maximum of 3 freeze/thaw cycles will be used. If a lower number of freeze/thaw cycles is requested by the manufacturer, data should be provided to TMDA to support the request.

4.3 Characterization of the Hepatitis B specimen reference panel

The HBsAg Specimen Evaluation Panel shall be characterized using a standardized combination of assays i.e. a testing algorithm. These results are used to determine the HBsAg status of each specimen for the purpose of the performance evaluation (Figure 1). Use of any other combination of assays for characterization of the HBsAg specimen evaluation panel shall be communicated, discussed, and agreed with TMDA beforehand.

Initially, each specimen is tested on the Murex HBsAg version 3 (DiaSorin S.p.A) and bioelisa HBsAg 3.0 (biokit S.A.) in parallel.

Specimens that were non-reactive on both EIAs are not further tested and are assigned as HBsAg negative.

Specimens with discrepant EIA results and with dually reactive EIA results are further tested on Murex HBsAg Confirmatory version 3 (DiaSorin S.p.A) to confirm the presence of HBsAg in specimens found initially reactive.

Specimens that were positive by neutralization are assigned as HBsAg positive.

Specimens that were negative by neutralization are assigned as HBsAg negative.
If the confirmatory results are unclear, the specimen will be omitted from the panel.




Figure 1. Testing algorithm for the characterization of the clinical specimen panel (serum/plasma) for the evaluation of HBsAg assays

5 Laboratory testing

Regarding evaluating rapid diagnostic tests, a ‘test run’ is defined as a consecutive run of simple/rapid diagnostic tests of the same production lot performed during the same ‘session’. A ‘testing session’ might be considered to be a morning or afternoon.

Kit controls, if available, and external quality controls are tested with (at the beginning of) each test run.

5.1 Review of the instructions for use

Each product under evaluation is used strictly in accordance with the instructions for use (IFU) issued by the manufacturer. The laboratory will send a hard or electronic copy of the IFU to TMDA upon delivery of the test kits and prior to the commencement of the laboratory evaluation. The IFU must be reviewed against the IFU submitted to TMDA as part of the dossier assessment for market authorization procedure. If the IFU has been updated since dossier submission, a letter from the manufacturer detailing changes made must be sent to TMDA prior to the laboratory evaluation commencing.

5.2 Clinical performance panel

The specimen reference panel is run in order that approximately one half of the specimen panel will be run with the one lot and the other half of the panel with the other lot. The specimens of the Hepatitis specimen reference panel should initially be tested in singular and in a blinded manner.

Specimens with invalid result should be retested in singular on the same lot.

Specimens which are found to be indeterminate by the criteria stated in the instructions for use (e.g. grey zone for EIAs) should be retested in duplicate on the same lot number of assay and singular on the other lot. In the case that the testing result cannot be resolved after all testing, the specimen is to be called indeterminate.

Specimens with results discrepant from the reference results are retested in duplicate using the same lot number by the same operator. The results that occur two out of three times are recorded as the test results. If the result is again discrepant, the specimen is retested on a second lot number, if available. If the result on the second lot is concordant with the reference result, no further testing is required.

In all cases of repeat testing, all results (initial and repeat testing) should be recorded.

5.3 Criteria to continue testing.

After testing the first 50 specimens (for rapid tests) an interim analysis is done, and results are communicated to TMDA. If less than 90% of the results are concordant with the reference results, then the evaluation is stopped, and troubleshooting should be done by TMDA and the manufacturer.

5.4 Lot-to-lot variation panel

Lot-to-lot variation is assessed by testing the same ten dilution series, as described in section 4, on two separate production lots of the assay under evaluation in the same testing session.

5.5 Interpretation of results

The interpretation of results for each assay under evaluation is made strictly according to the manufacturers' instructions within the IFU. Invalid test results are recorded on the data collection sheets including where the control line does not appear or in any other way the test result is invalid as defined by the IFU. For test results that are indeterminate according to the IFU, the results are recorded on data collection sheets.

Visual interpretation of results of subjectively read assays is made independently by three readers (without the knowledge of the other two sets of results and blinded to the reference result for the specimen) and entered onto the data collection sheets. These results are compared by the operator carrying out the assay so that any mistakes may be identified and rectified immediately. Should recording errors be identified, both the original and corrected result are recorded and initialed by the reader. When the three readers interpret the results differently from each other (i.e. reactive/non-reactive), the consensus is recorded as that interpretation which occurs two out of three times. In cases where all three interpretations are different, the result is recorded as indeterminate.

5.6 Recording test results

All test results are recorded on standardized test result worksheets and then entered in a Microsoft Excel spreadsheet for further data analysis.

For subjectively read assays such as rapid diagnostic tests the intensity of band/line/spot is additionally entered into the data collection sheet. The intensity rating system reads as described in Table 2.

Table 1. Result legend for subjectively read assays.

Scoring index	Intensity reading scale
0	Non-reactive
1	Very Weak
2	Weak
3	Medium to Strong Reactivity
7	Invalid

6 Quality control and interpretation of test results

6.1 Test kit controls.

Manufacturer/Applicant supplied positive and negative test kit controls will be run as indicated in the IFU for all test formats included in each test run for EIAs and at the commencement of each testing session for rapid diagnostic tests and other formats. Where positive and negative test kit controls are not supplied by the manufacturer/applicant, as will be the case for many rapid diagnostic tests, the external quality control specimen will act at the control specimen.

6.2 Internal control lines for rapid diagnostic tests

Generally, rapid diagnostic tests contain a control band, line or spot to determine migration of the reagents, or the sample has occurred. Most control bands/lines/spots will become visible with the addition of reagent (i.e. buffer). However, some rapid diagnostic tests will contain a control band/line that becomes visible with addition of specimen (i.e. presence of IgG). It is imperative that the exact nature of the control band/line is ascertained and included in the report. An experiment is performed to verify this point, if not explicitly mentioned in the IFU.

6.3 External quality control specimen

The laboratory will supply an external quality control (QC) specimen which is tested in singular at the beginning of each test session for rapid diagnostic tests. The QC specimen represents a weakly reactive Hepatitis B positive sample. The QC specimen is prepared by the laboratory or acquired commercially, depending on the assay under evaluation.

6.4 Competency panels

User competency must be established for each assay by each operator before the evaluation commences. This may be established at the time of assay demonstration by the manufacturer or for training purposes.

6.5 Limits of acceptability

All results on test kits controls and QC specimens are entered on the data collection sheets. Should the test kit controls or the QC specimen not give results within the expected ranges, evaluation testing on that assay is suspended until the cause has been identified and a satisfactory solution identified. Such problems must be communicated immediately to TMDA and recorded on the data sheets. The PI is responsible for carefully checking all data entry forms for legibility, accuracy and completeness.

7 Analysis of data

7.1 Invalid devices

The number of invalid devices (for rapid diagnostic test) is recorded as the number of invalid test devices as a percentage of the total number of devices used for the evaluation testing with clinical specimens (excluding, lot to lot variation panels).

Invalid results may mean invalid test results as defined by the instructions for use such as where the control line/band does not appear or invalid due to obviously defective test device or defective transfer pipette.

7.2 Inter-reader variability

The inter-reader variability is calculated when test results must be read without any objective reading instruments i.e. rapid diagnostic tests. Three persons independently interpret each test result. The inter-reader variability is expressed as the percentage of specimens for which initial test results are differently interpreted (i.e. reactive or non-reactive or indeterminate, if applicable) by the independent readers for the clinical specimens (excluding commercially acquired panels, TMDA reference preparations, culture supernatant panels, lot to lot variation panels).

8 Clinical performance characteristics

The following strategies are used to calculate the clinical performance characteristics by comparing the results of the assay under evaluation and reference testing results on the clinical specimen panel.

Table 2. 2 x 2 table for calculation of performance characteristics

Results of assay under evaluation	Reference testing results			
		HBsAg-positive	HBsAg-negative	Total
	Reactive	a (true positives)	b (false positives)	a + b
	Non-reactive	c (false negatives)	d (true negatives)	c + d
	Total	a + c	b + d	a+b+c+d

8.1 Sensitivity

Sensitivity is the ability of the assay under evaluation to detect correctly specimens that contain the analyte (reference results positive). Thus, sensitivity is the number of true positive specimens identified by the assay under evaluation as positive (a), divided by the number of specimens identified by the reference assays as positive (a+c), expressed as a percentage.

$$\text{Sensitivity} = \frac{a}{a + c} \times 100\%$$

8.2 Specificity

Specificity is the ability of the assay under evaluation to detect correctly specimens that do not contain the analyte (reference results negative). Thus, specificity is the number of true negative specimens identified by the assay under evaluation as negative (d), divided by the number of specimens identified by the reference assays as negative (b+d), expressed as a percentage.

$$\text{Specificity} = \frac{d}{b + d} \times 100\%$$

8.3 Confidence intervals

The exact 95% confidence intervals for binomial proportions are calculated for both sensitivity and specificity.

8.4 Initial and final sensitivity and specificity

The initial sensitivity and specificity are calculated based on the initial results obtained for the assay under evaluation (except for invalid results, for which the result of repeated testing is used). If the initial result is indeterminate, then the specimen is excluded from this analysis. The proportion of initial indeterminate results is reported.

The final sensitivity and specificity values are calculated taking into consideration the repeat testing performed on the same lot and further testing second lot of the assay under evaluation, if applicable (i.e. for specimens with initial indeterminate or discrepant results).

9 Analytical performance characteristics

9.1 Results from lot-to-lot variation panel

The results of the lot-to-lot panel for the two production lots are compared and a variation of +/- 1 dilution series is considered acceptable. The number of series with acceptable and non-acceptable variation is reported.

10 Laboratory professional's appraisal

The technical aspects of the assay under evaluation are assessed by the Laboratory professional(s) who performed the testing. These assessments, along with other selected assay characteristics, contribute to an overall appraisal of each assay's suitability for use in small laboratories. To enable comparison between assays, a scoring system is used to rate specified operational characteristics (Annex 1).

11 Report preparation and dissemination.

The preliminary data analysis and drafting of the report will be carried out by the evaluating laboratory according to pre-defined report templates.

The draft report will be shared simultaneously with TMDA and the manufacturer.

12 Acceptance criteria

The following criteria will be used to assess the assay under evaluation. Other parameters included in this evaluation are provided for information but are not used as pass/fail criteria for this assessment.

Table 3. Minimum acceptable performance for HBsAg serology assays in the TMDA prequalification performance evaluation

Parameter	Rapid diagnostic tests
Initial sensitivity estimate	≥ 99%
Final specificity estimate	≥ 98%
Inter-reader variability	≤5%
Invalid rate	<5%

13 Materials and supplies

The manufacturers of products will provide the products and any equipment necessary for the evaluation free of charge.

Table 4. Number of tests required to perform this evaluation.

	Lot A	Lot B
Clinical panel	700	700
Lot-to-lot variation	100	100
Total	800	800
Total + 20% for controls and repeats (for antigen detecting assays)		

14 Roles and responsibilities

14.1 Responsibilities of the Evaluating Laboratory

- Ensure availability of Hepatitis B specimen reference panel, lot-to-lot variation, panel;
- Conducting the performance evaluation in accordance with internationally recognized best practice;
- Preparation of QC specimens and proficiency panels;
- Preparation of draft report on laboratory evaluation;
- Advising TMDA on operational characteristics of assays evaluated.

All source data, data analysis records and all correspondence are retained and archived for a period of at least ten years.

14.2 Responsibilities of TMDA

- Technical advice to the PI;
- Technical and administrative management of the laboratory evaluation;

- iii. Verification of the draft report, seeking of comments from manufacturer in case of List one laboratories;
- iv. Preparation and dissemination of the final report;
- v. Formal contacts with authorized contacts of the manufacturers.

15 Bibliography

Armitage P, Berry G, Matthews, JNS, Statistical Methods in Medical Research, 4th Edition. Blackwell Scientific Publications, Oxford, 2002

Kirkwood B, Stern J, Essential Medical Statistics 2nd edition, Blackwell Science Ltd. 2003

WHO. Guidance on regulations for the transport of infectious substances 2021-2022. <https://iris.who.int/bitstream/handle/10665/339825/9789240019720-eng.pdf?sequence=1>

WHO. Guidance for procurement of in vitro diagnostics and related laboratory items and equipment. <https://iris.who.int/bitstream/handle/10665/255577/9789241512558-eng.pdf?sequence=1>

EN 13612:2002 Performance evaluation of in vitro diagnostic medical devices

ISO 17025 (General requirements for the competence of testing and calibration laboratories)

ISO15189 (Medical laboratories — Particular requirements for quality and competence)

16 Annex 1

16.1 Operational characteristics and ease of use

This assay requires/does not require laboratory equipment and can/cannot be performed in laboratories with limited facilities or in non-laboratory settings. *If applicable, add specifics on why it cannot be used in laboratories with limited facilities: e.g. the instrument requires a stable source of electricity and significant physical space. Furthermore, training and implementation of good laboratory practice is essential to obtaining accurate results. If technical support was needed during evaluation: Adequate technical support from manufacturer or representative is critical.*

The assay was found easy to use / not easy to use by the operators performing the evaluation. *If applicable, add specific information provided in comments in the ease of use table.*

For RDTs (and ELISA)

Key operational characteristics	
Number of steps*	X steps in total X steps with precision pipetting (<i>only for serum/plasma</i>)
Time to result	X minutes
Endpoint stability (interval)	X minutes (the test can be read between xx and xx minutes after addition of specimen/diluent)

Internal QC	Yes/no, <i>insert brief description. [The test has an internal control line. The presence of the control line indicates that migration of liquid has occurred; however, it does not guarantee that the correct specimen type or volume was added or that the test procedure was followed correctly.]</i>
-------------	--

* *Definition: each action required to obtain a result (excluding specimen collection, device preparation – opening the pouch), e.g. for RDTs: add specimen, add buffer (2 steps).*

For instrument-based assays

Key operational characteristics	
Number of steps for one specimen*	X steps in total X steps with precision pipetting
Number of steps for instrument management**	X steps per run/day
Time to result for one test/run	X minutes
Operator hands-on time for one test/run	X minutes
Level of automation	
Quality controls	QC are/are not provided by the manufacturer and should be purchased separately. <i>Add information on type of QC (eg. high positive, low positive, negative)</i>
Operating temperature	xx- xx °C, any comments on temperature stability of conducting the test.
Result display and connectivity	Results are displayed on the instrument / connected computer. They may be printed using a standard/specific printer. The results can be exported to the laboratory information system and other health information systems.
Power sources	Main power / Battery / Solar power The use of a UPS is recommended, as stable electricity is required
Biosafety (<i>outside of infectious specimen handling</i>)	Operators reported no biosafety concerns for the user. <i>Add information if applicable</i>
Waste	The volume of liquid was is approx. xx per test/run. The volume of solid waste is approx. xx per test/run. Waste disposal requires / does not require specific measures in addition to usual laboratory biohazard waste disposal procedures. <i>Add information if applicable.</i>
Calibration	Calibrators are/are not provided by the manufacturer and should be purchased separately. <i>Add frequency of calibration recommended.</i>
Maintenance	Daily / Weekly / Monthly / Yearly / No maintenance is required.

Other specific requirements	<i>If applicable (eg. space requirements, weight to surface area ratio, installation by manufacturer)</i>
-----------------------------	---

All rights reserved:

This is a controlled document. It must not be copied without authorization from the Manager, Quality and Risk Management or Director General.

Only originals or authorized copies shall be used as working documents.